Sensorion (STU:RFM) Construction In Progress: €0.00 Mil (As of Dec. 2025)


STU:RFM Sensorion SA STU:RFM
28 GF Score
Price €0.24
GF Value €0.43
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Sensorion Construction In Progress?

Sensorion STU:RFM +1.29% 28 Construction In Progress is €0.00 Mil as of Dec. 2025. GuruFocus rates STU:RFM with a GF Score™ of 28/100 and a GF Value™ of €0.43 (Possible Value Trap). The stock has 1 warning sign investors should review.

Sensorion's annual construction in progress declined from Dec. 2023 (€0.39 Mil) to Dec. 2024 (€0.00 Mil) but then stayed the same from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€0.00 Mil).

Sensorion Construction In Progress Historical Data

* Premium members only.

The historical data trend for Sensorion's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sensorion Construction In Progress Chart

Sensorion Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.00 0.39 0.00 0.00

Sensorion Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.23 0.00 0.00 0.00
STU:RFM
28GF Score
Sensorion SA STU:RFM
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sensorion Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0.00 Mil mean?
Sensorion (STU:RFM) has a Construction In Progress of €0.00 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Sensorion and its competitors.
Is Sensorion's Construction In Progress too high?
Sensorion's current Construction In Progress is €0.00 Mil. Overall, Sensorion has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sensorion's Construction In Progress compare to VRTX and REGN?
Sensorion's Construction In Progress of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Sensorion and its competitors. Sensorion's current Construction In Progress is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensorion stock overvalued right now?
Based on GuruFocus' analysis, Sensorion (STU:RFM) is currently considered Possible Value Trap. The stock's GF Value™ is €0.43, compared to a current price of €0.24 — trading 45.2% below its estimated fair value. The current Construction In Progress is €0.00 Mil. Sensorion's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Sensorion (STU:RFM), the current Construction In Progress is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sensorion (STU:RFM) Overvalued in 2026?

Based on GuruFocus' analysis, Sensorion stock appears to be undervalued. The current stock price of €0.24 is trading 45.2% below its estimated GF Value™ of €0.43. GuruFocus considers Sensorion to be Possible Value Trap.

Key valuation signals for STU:RFM:

  • Construction In Progress: €0.00 Mil
  • GF Value™: €0.43 vs. price of €0.24 (45.2% below fair value)
  • GF Score™: 28/100 with 1 warning sign

No single metric tells the full story. See the STU:RFM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sensorion Business Description

Other Exchanges ALSEN:France
Address 375, rue du Professeur Joseph Blayac, Montpellier, FRA, 34080
Sensorion SA is a France-based clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders. The SENS501 (OTOF-GT) targets deafness caused by mutations of the gene encoding for otoferlin and is currently developed in a Phase 1/2 clinical study, and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. The company's pipeline programs are OTOF-GT (SENS-501), GJB2-GT, GJB2-GT, GJB2-GT, TREAT AND PREVENT, SENS-401 COCHLEAR, SENS-401 CIO, and SENS-401 SSNHL.
28GF Score

Get the complete analysis for STU:RFM

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.24
Price
€0.43
GF Value